A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naive Subjects With Follicular Lymphoma
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms PERSPECTIVE
- Sponsors Pharmacyclics
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 10 Mar 2017 Status changed from not yet recruiting to recruiting.
- 03 Nov 2016 New trial record